Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomos...
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with keyhole minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reprodu...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
aortoseal
A minimally invasive and durable endograft fastening solutio...
6M€
Cerrado
NIMBLE System
"The NIMBLE System: A novel non-invasive and non-ionizing me...
3M€
Cerrado
PCIN-2013-068
CATETERES INTELIGENTES EN SISTEMAS AVANZADOS PARA INTERVENCI...
25K€
Cerrado
CG-100
Temporary intraluminal bypass device designed to reduce the...
3M€
Cerrado
FCDC13-1E-2140
Sistemas de coagulación para aplicación por cirugía de mínim...
33K€
Cerrado
NIMBLE WOMENTECHEU
A novel non-invasive and non-ionizing medical device for mon...
75K€
Cerrado
Información proyecto ELANA®
Duración del proyecto: 24 meses
Fecha Inicio: 2022-09-29
Fecha Fin: 2024-09-30
Líder del proyecto
AMT MEDICAL RESEARCH BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with keyhole minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery
without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.